Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 8,458 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism Disorder, Glucose Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 97
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Metabolic Syndrome, Autonomic Neuropathy
Interventions: Balance exercise, Standard care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, Diabete Mellitus
Interventions: Measure of physiologic parameters; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Overweight
Interventions: Decaffeinated coffee, Caffeinated coffee, No coffee; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome
Interventions: Ultrafine Air Pollution Particulate Matter, Filtered Air; Other
Lead sponsor: David Diaz-Sanchez; Federal
Eligibility: 25 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metabolic Syndrome
Interventions: lifestyle intervention; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 25 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Lawrence, Massachusetts

Conditions: Hypoglycemia, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 20 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Bromocriptine mesylate; Drug
Lead sponsor: VeroScience; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more

Conditions: Diabetes Mellitus, Cardiovascular Diseases
Interventions: Algorithm driven medication titration, Monitoring, Group support, Self efficacy; Other · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: West Haven, Connecticut • Honolulu, Hawaii • Providence, Rhode Island

Conditions: Diabetes Mellitus, Type 2
Interventions: Peer Leader Diabetes Self-Management Support, Virtual Diabetes Self-Management Education; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 55 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabete Type 2, Pre Diabetes
Interventions: PomJuice, Water, Sugar Water; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metabolic Syndrome X
Interventions: Astaxanthin, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Coronary Artery Disease, Hypertension, Dyslipidemia, Diabetes
Interventions: magnesium L-lactate; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Diabetes Mellitus
Interventions: cell phone delivered tele-educational, cell phone; Device
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatitis, Chronic; Diabetes; Transplant
Interventions: etanercept, Alpha 1-Antitrypsin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Scorecard, Control; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 40 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin QD (once daily) for 7 days; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 6
States / cities: Cypress, California • DeLand, Florida • Miami, Florida + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Chronic Lifestyle Related Disease, Diabetes, Overweight and Obesity, Dyslipidemias, Hypertension, Cardiovascular Diseases
Interventions: Lifestyle Medicine; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: iDSMES, Standard of Care; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 13 Years to 84 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Cardiovascular Risk Factor, Insulin Resistance, PreDiabetes, Diabetes, Coronary Artery Disease, Hypertension, Prehypertension, Dyslipidemias
Interventions: Use of HealthPals (Telemedicine supported by digital health platform); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed Loop; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Metabolic Syndrome and Fall Risk

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance

Physiological Changes in Adults With Metabolic Syndrome Exposed to Ultrafine Air Particles

Lawrence Latino Diabetes Prevention Project

Hippocampal Metabolism and Function in Patients With Type 1 Diabetes

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

Pharmacist-led Group Medical Visits to Help With Diabetes Management

Michigan Men's Diabetes Project

Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control

The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Diabetes Scorecard Educational Intervention Study

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Evaluation of a Lifestyle Medicine Practice

A Comprehensive Community Approach for Diabetes Prevention and Care for a Vulnerable Population in Galveston

Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology

Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia